Prosecution Insights
Last updated: November 04, 2026
Application No. 18/298,800

Combination Therapies for Treating Cancer

Non-Final OA §103§DOUBLEPATENT
Filed
Apr 11, 2023
Priority
Nov 19, 2020 — CN PCT/CN2020/130149 +3 more
Examiner
CHONG, YONG SOO
Art Unit
1623
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Guangzhou Healthquest Pharma Co. Ltd.
OA Round
1 (Non-Final)
44%
Grant Probability
Moderate
1-2
OA Rounds
4m
Est. Remaining
86%
With Interview

Examiner Intelligence

Grants 44% of resolved cases
44%
Career Allowance Rate
391 granted / 893 resolved
-16.2% vs TC avg
Strong +42% interview lift
Without
With
+41.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
55 currently pending
Career history
961
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
52.7%
+12.7% vs TC avg
§102
21.2%
-18.8% vs TC avg
§112
17.5%
-22.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 893 resolved cases

Office Action

§103 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Application Applicant's election of Group I, drawn to a method of treating a hematological malignancy by administering a compound of formula I and an allosteric inhibitor, in the reply filed on 6/23/26 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Claims 1-2, 5-10, 14, 17-22, 26-27, 38, 40, 43 are pending. Claims 22, 26-27, 38, 40, 43 have been withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Claims 1-2, 5-10, 14, 17-21 are examined herein insofar as they read on the elected invention and species. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-2, 5-10, 14, 17-21 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-10 of U.S. Patent No. 12,544,370 in view of Hughes et al. (“Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure,” N. Eng. J. Med. 2019, 381, 2315-2326). The referenced claims recite a method of treating chronic myeloid leukemia caused by BCR-ABL mutation that is resistant to ponatinib, wherein the mutation is T315I, by administering a compound of formula IA (same structure as the claimed HQP-1351). However, the referenced claims fail to disclose the allosteric inhibitor, asciminib. Hughes et al. teach that asciminib is an allosteric inhibitor that binds a myristoyl site of the BCR-ABL1 protein, locking BCR-ABL1 into an inactive conformation through a mechanism distinct from those for all other ABL kinase inhibitors. Asciminib was active in treating patients with CML who had resistance to tyrosine kinase inhibitors (page 2315). Therefore, it would have been prima facie obvious to a person of ordinary skill in the art, at the time the claimed invention was made, to have combined the compound of formula IA, with asciminib, as taught by Hughes et al., in the method of treating a patient with CML resistant to tyrosine kinase inhibitors caused by T315I mutation. A person of ordinary skill in the art would have been motivated to combine the compound of formula IA with asciminib because both are individually known to be useful for treating CML resistant to tyrosine kinase inhibitors caused by T315I mutation. Therefore, one of ordinary skill in the art would have had a reasonable expectation of success in treating CML resistant to tyrosine kinase inhibitors caused by T315I mutation by the combined therapeutically additive effect of two known active agents being used for the same purpose. Claims 1-2, 5-10, 14, 17-21 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1, 6-14, 16-21, 36-37 of copending Application No. 19/422,564 in view of Hughes et al. (“Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure,” N. Eng. J. Med. 2019, 381, 2315-2326). The referenced claims recite a method of treating chronic myeloid leukemia caused by BCR-ABL mutation that is resistant to tyrosine kinase inhibitors, wherein the mutation is T315I, by administering a compound of formula IA (same structure as the claimed HQP-1351). However, the referenced claims fail to disclose the allosteric inhibitor, asciminib. Hughes et al. teach that asciminib is an allosteric inhibitor that binds a myristoyl site of the BCR-ABL1 protein, locking BCR-ABL1 into an inactive conformation through a mechanism distinct from those for all other ABL kinase inhibitors. Asciminib was active in treating patients with CML who had resistance to tyrosine kinase inhibitors (page 2315). Therefore, it would have been prima facie obvious to a person of ordinary skill in the art, at the time the claimed invention was made, to have combined the compound of formula IA, with asciminib, as taught by Hughes et al., in the method of treating a patient with CML resistant to tyrosine kinase inhibitors caused by T315I mutation. A person of ordinary skill in the art would have been motivated to combine the compound of formula IA with asciminib because both are individually known to be useful for treating CML resistant to tyrosine kinase inhibitors caused by T315I mutation. Therefore, one of ordinary skill in the art would have had a reasonable expectation of success in treating CML resistant to tyrosine kinase inhibitors caused by T315I mutation by the combined therapeutically additive effect of two known active agents being used for the same purpose. This is a provisional obviousness-type double patenting rejection. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action: (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made. The factual inquiries set forth in Graham vs John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a). Claims 1-2, 5-10, 14, 17-21 are rejected under 35 U.S.C. 103(a) as being obvious over Ren et al. (“Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region−Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib,” J. Med. Chem. 2013, 56, 879-894) in view of Hughes et al. (“Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure,” N. Eng. J. Med. 2019, 381, 2315-2326). The instant claims are directed to a method of treating a hematological malignancy by administering a compound of formula I and an allosteric inhibitor. Ren et al. teach that GZD824 (same structure as the claimed HQP-1351) is a novel orally bioavailable inhibitor against broad spectrum Bcr-Abl mutants, including T315I, in patients with chronic myelogenous leukemia (CML) having imatinib resistance. Results show good oral bioavailability, reasonable half-life, and promising in vivo antitumor efficacy (abstract). Ren et al. also teach that several small molecules are capable of inhibiting Bcr-Abl mutant, such as the allosteric inhibitor, GNF-2 (page 880, left column, first paragraph). However, Ren et al. fail to disclose the allosteric inhibitor, asciminib. Hughes et al. teach that asciminib is an allosteric inhibitor that binds a myristoyl site of the BCR-ABL1 protein, locking BCR-ABL1 into an inactive conformation through a mechanism distinct from those for all other ABL kinase inhibitors. Asciminib was active in treating patients with CML who had resistance to tyrosine kinase inhibitors (page 2315). Therefore, it would have been prima facie obvious to a person of ordinary skill in the art, at the time the claimed invention was made, to have combined GZD824, as taught by Ren et al., with asciminib, as taught by Hughes et al., in the method of treating a patient with CML resistant to tyrosine kinase inhibitors caused by T315I mutation. A person of ordinary skill in the art would have been motivated to combine GZD824 with asciminib because both are individually known to be useful for treating CML resistant to tyrosine kinase inhibitors caused by T315I mutation. Therefore, one of ordinary skill in the art would have had a reasonable expectation of success in treating CML resistant to tyrosine kinase inhibitors caused by T315I mutation by the combined therapeutically additive effect of two known active agents being used for the same purpose. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yong S. Chong whose telephone number is (571)-272-8513. The examiner can normally be reached Monday to Friday: 9 AM to 5 PM EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Adam Milligan, can be reached at (571)-270-7674. The fax phone number for the organization where this application or proceeding is assigned is (571)-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at (866)-217-9197 (toll-free). /Yong S. Chong/Primary Examiner, Art Unit 1623
Read full office action

Prosecution Timeline

Apr 11, 2023
Application Filed
Sep 18, 2026
Non-Final Rejection mailed — §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778957
COMPOSITION FOR ENHANCING INTRA-CELLULAR NITRIC OXIDE GENERATION
3y 5m to grant Granted Nov 03, 2026
Patent 12734158
APPLICATION OF RILUZOLE- AND BORNEOL-CONTAINING COMPOSITION IN PREPARATION OF MEDICATION FOR TREATING CEREBROVASCULAR DISEASES
3y 2m to grant Granted Sep 15, 2026
Patent 12721846
METHODS FOR TREATING BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS IN PATIENTS WITH DEMENTIA
4y 3m to grant Granted Sep 01, 2026
Patent 12714700
METHODS OF TREATING RBP4 RELATED DISEASES WITH TRIAZOLOPYRIDINES
2y 5m to grant Granted Aug 25, 2026
Patent 12691087
METHOD OF ENHANCING GLUCOSE LEVELS IN THE CENTRAL NERVOUS SYSTEM
7y 1m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
44%
Grant Probability
86%
With Interview (+41.7%)
3y 11m (~4m remaining)
Median Time to Grant
Low
PTA Risk
Based on 893 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month